Culled from the broadcast"It is truly astonishing to me that Leronlimab appears to be performing...at the outer limits of what I even thought was possible."
"I could not be more excited by what we are seeing."
"And of course, as these data become known and more widely disseminated, we will continue to evaluate potential opportunities for strategic partnerships."
"And then I would add, that we've had very productive conversations with the I-SPY network, and they too, are very keen to start a study in Leronlimab again in HER2-negative patients with breast cancer, BUT, they are looking at neoadjuvant setting, so NEWLY identified patients a month before they go to surgery might benefit from using Leronlimab as a monotherapy."
"This was originally imagined as a way to sort quickly and prospectively confirm the PD-L1 we were seeing with Leronlimab that some Potential Industry Partners had asked to see."
"And as I have said, 5 out of 5patients who upregulated and received a checkpoint inhibitor are alive now 5 plus years later." It is also true, that 100% of the patients who didn't upregulate because they got the lower dose or they didn't receive the checkpoint inhibitor, which was kind of arbitrary given by the oncologists who were just shooting for whatever they could.
100% of those individuals unfortunately, are now deceased."
There's more...butt, I think We all get the point.
"I could not be more excited by what we are seeing."
"And of course, as these data become known and more widely disseminated, we will continue to evaluate potential opportunities for strategic partnerships."
"And then I would add, that we've had very productive conversations with the I-SPY network, and they too, are very keen to start a study in Leronlimab again in HER2-negative patients with breast cancer, BUT, they are looking at neoadjuvant setting, so NEWLY identified patients a month before they go to surgery might benefit from using Leronlimab as a monotherapy."
"This was originally imagined as a way to sort quickly and prospectively confirm the PD-L1 we were seeing with Leronlimab that some Potential Industry Partners had asked to see."
"And as I have said, 5 out of 5patients who upregulated and received a checkpoint inhibitor are alive now 5 plus years later." It is also true, that 100% of the patients who didn't upregulate because they got the lower dose or they didn't receive the checkpoint inhibitor, which was kind of arbitrary given by the oncologists who were just shooting for whatever they could.
100% of those individuals unfortunately, are now deceased."
There's more...butt, I think We all get the point.
18